MannKind's ROE % for the quarter that ended in Dec. 2023 was Negative Equity. MannKind's PB Ratio for the quarter that ended in Dec. 2023 was N/A.
MannKind's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was Negative Equity.
MannKind ROE % Adjusted to Book Value Historical Data
The historical data trend for MannKind's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MannKind's ROE % Adjusted to Book Value
For the Biotechnology subindustry, MannKind's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MannKind's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MannKind's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where MannKind's ROE % Adjusted to Book Value falls into.
MannKind ROE % Adjusted to Book Value Calculation
MannKind's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MannKind ROE % Adjusted to Book Value Related Terms
Thank you for viewing the detailed overview of MannKind's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MNKD has been successfully added to your 